NCT02982005View on ClinicalTrials.gov

A Study of KHK4827 (Brodalumab) in Subjects With Moderate to Severe Psoriasis in Korea

PHASE3CompletedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

January 31, 2017

Primary Completion Date

August 14, 2018

Study Completion Date

August 14, 2018

Conditions
Moderate to Severe Plaque Psoriasis
Interventions
DRUG

KHK4827

Administered KHK4827 by subcutaneous (SC) injection until week 62.

DRUG

Placebo

Administered placebo by subcutaneous (SC) injection until week 12. Administered KHK4827 by SC injection from week 13 until week 62.

Trial Locations (1)

49241

Korea, Republic of, Seoul

All Listed Sponsors
lead

Kyowa Kirin Korea Co., Ltd.

INDUSTRY

NCT02982005 - A Study of KHK4827 (Brodalumab) in Subjects With Moderate to Severe Psoriasis in Korea | Biotech Hunter | Biotech Hunter